Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer

This publication has 29 references indexed in Scilit:

• Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy
  Biomaterials, 2011
• Nanomedicine
  New England Journal of Medicine, 2010
• Superparamagnetic iron oxide – Loaded poly (lactic acid)-d-α-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent
  Biomaterials, 2010
• Nanoparticle therapeutics: an emerging treatment modality for cancer
  Nature Reviews Drug Discovery, 2008
• Nanocarriers as an emerging platform for cancer therapy
  Nature Nanotechnology, 2007
• Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer
  Journal of Clinical Oncology, 2006
• Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release
  Biomaterials, 2006
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
  Oncogene, 1999
• HER2-Targeted Gene Transfer
  Human Gene Therapy, 1997